Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Main Authors: | D Papaioannou, R Rafia, J Rathbone, M Stevenson, H Buckley Woods, J Stevens |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2012-10-01
|
Series: | Health Technology Assessment |
Online Access: | https://doi.org/10.3310/hta16370 |
Similar Items
-
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
by: A Boland, et al.
Published: (2009-09-01) -
Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
by: Y Dundar, et al.
Published: (2009-06-01) -
Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
by: Aguiar-Bujanda D, et al.
Published: (2015-10-01) -
Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation
by: B. Wake, et al.
Published: (2002-01-01) -
Maintenance rituximab in Veterans with follicular lymphoma
by: Ahmad S. Halwani, et al.
Published: (2020-10-01)